GALNAC4S-6ST antibody
- Known as:
- GALNAC4S-6ST (anti-)
- Catalog number:
- 70r-5944
- Product Quantity:
- USD
- Category:
- -
- Supplier:
- Fitzgerald industries international
- Gene target:
- GALNAC4S-6ST antibody
Related products to: GALNAC4S-6ST antibody
Related articles to: GALNAC4S-6ST antibody
- Atherosclerosis, a chronic inflammatory arterial disease, involves complex interactions among diverse immune cells. Although single-cell RNA sequencing (scRNA-seq) has revealed cellular heterogeneity within atherosclerotic lesions, the diversity of neutrophils and their crucial genes in atherogenesis remain elusive. - Source: PubMed
Publication date: 2026/03/02
Wang PingFu QiangCai YuefengYang JiaxinCui ZhenzhenSun QiyuQiu QuanliMa XiaowenLi Min - Castration-resistant prostate cancer (CRPC) remains a major clinical challenge, as tumor growth persists despite androgen receptor (AR) pathway inhibition. Glycosaminoglycans, particularly chondroitin sulfate (CS), are increasingly recognized as modulators of oncogenic signaling. However, the contribution of distinct sulfation motifs to therapeutic resistance is poorly understood. Here, we identify the CS-E motif as a critical regulator of IL-6/STAT3 signaling and a driver of hormone-independent growth in CRPC. - Source: PubMed
Publication date: 2026/01/13
Ota HayatoYamamoto KazuoNishihara Shoko - Adrenoleukodystrophy (ALD) is a rare X-linked neurogenetic disease caused by mutations in the ATP-binding cassette subfamily D member 1 () gene. Currently, the molecular mechanisms underlying the onset and severity of ALD remain unclear. Therefore, the aim of this study is to identify information on candidate genes associated with the onset and severity of ALD by transcriptome sequencing of whole blood samples from monozygotic twin families with the disease. - Source: PubMed
Publication date: 2025/10/31
Fu ChuhuaSu QiuyuChen YinglianZhang YonghuiZhang YanCao YingWang XinggangZhen ZhimingLiu ChenYang ZhaoYin ChanglinTan Liang - In the United States, African Americans (AA) have higher Pancreatic ductal adenocarcinoma (PDAC) incidence and mortality rates than Caucasian Americans (CA). This study aimed to identify distinct gene expression signatures and differentially regulated pathways in AA and CA PDACs. - Source: PubMed
Publication date: 2025/07/04
Bajpai PrachiPaluri RaviDiffalha Sameer AlChandrashekar Darshan SAfaq FarrukhOtali DennisElkholy AmrMiller C RyanPeter ShajanManne AshishNagaraju Ganji PurnachandraSaddala Madhu SudhanaKhushman Moh'dVarambally SooryanarayanaManne Upender - Tumor stromal remodeling is an obstacle for immune checkpoint inhibitors (ICI). A stroma modifying small interfering RNA (siRNA) to carbohydrate sulfotransferase 15 (CHST15) was recently shown to enhance tumor-infiltrating T cells, yet its impact on antitumor response of ICI remains unexplored. In mouse pancreatic cancer KPC and Pan02 subcutaneous syngeneic tumor models, mice were divided into 4 groups for treatment; (1) control, (2) CHST15 siRNA monotherapy, (3) anti-programmed death receptor 1 (PD-1) monotherapy, and (4) combination therapy with CHST15 siRNA and anti-PD-1 antibody. Mice were sacrificed after 2 week-treatments and anti-tumor effects were evaluated by immunohistochemistry for KPC and flow cytometry for Pan02 model, respectively. In the KPC model, combination treatment with intratumoral CHST15 siRNA (0.9-1.0 mg/kg) and systemic anti-PD-1 antibody (5 mg/kg) synergistically and robustly suppressed tumor growth with a significant increase of tumor-infiltrating CD4 and CD8 T cells compared to anti-PD-1 monotherapy. In the Pan02 model, combination treatment with CHST15 siRNA and anti-PD-1 showed anti-tumor effect with significant increases in % necrosis area of the tumor, and tumor-infiltrating T cells compared to the control. Notably, the combination therapy dramatically diminishes Ly6CLy6G granulocytic myeloid-derived suppressor cells (MDSCs) compared to anti-PD-1 monotherapy. The present study demonstrated the robust synergy between systemic anti-PD-1 antibody and a single stroma modifying agent. Combination usage of intratumoral CHST15 siRNA would provide a novel therapeutic option to trigger the remarkable effect of ICI on this most hard-to-treat solid tumor. - Source: PubMed
Publication date: 2025/07/01
Ye JuanjuanSuizu FutoshiYamakawa KeikoYoneyama HiroyukiKondo JiroKato MotohikoNishiyama AkiraYahagi NaohisaKadota Kyuichi